# Hillhurst Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hillhurst-biopharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.hillhurstbio.com
- Total disclosed funding: $1.8M
- Latest round: Seed (Sep 11, 2023)
- Investors on record: 1

## About

Based in California, US, and founded in 2021 by Chief Executive Officer Andrew Gomperts and Chairman Edward Gomperts, Hillhurst Biopharmaceuticals, Inc. operates as a biopharmaceutical company providing therapeutic gases to treat patients with sickle cell disease. IIn?May 2025,?Hillhurst Biopharmaceuticals, Inc.?received?USD 6.3 million?in?grant?funding?from new investors the Michael J. Fox Foundation and the Farmer Family Foundation. Hillhurst Biopharmaceuticals, Inc. develops a Glass technology platform addresses the limitations of inhaled gases, ensuring accurate dosing without the risks associated with traditional inhalation methods. The company creates liquid drug products containing concentrations of the targeted therapeutic gas. In addition, the firm provides a variety of programs such as HBI-002, HBI-137, HBI-201, and others. Hillhurst Biopharmaceuticals, Inc. offers therapies and treatment for a variety of diseases such as sickle cell disease, parkinson’s disease, cardio protection from doxorubicin toxicity, kidney transplant, and acute pain. The company plans to utilize the May 2025 funding to assist its Phase 2a clinical study for Parkinson's disease.

## Funding rounds

- Seed, Sep 11, 2023, $1.8M — Friedman Bioventures

## Investors

- Friedman Bioventures (https://capitalatlas.ai/funds/friedman-bioventures) — Seed